Metabolism of very-low-density lipoprotein and chylomicrons by streptozotocin-induced diabetic rat heart: Effects of diabetes and lipoprotein preference

American Journal of Physiology - Endocrinology and Metabolism

Volumn 295, Issue 5, 2008, Pages

  Niu, You Guo ^a,b   Evans, Rhys D ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN C; APOLIPOPROTEIN E; CHYLOMICRON; HEPARIN; PROTEIN HRLPL; STREPTOZOCIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE OXIDATION; HEART FUNCTION; HEART MUSCLE; ISOLATED HEART; LIPID STORAGE; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT;

ANIMALS; APOLIPOPROTEINS; BLOOD GLUCOSE; BODY WEIGHT; CHYLOMICRONS; CORONARY CIRCULATION; DIABETES MELLITUS, EXPERIMENTAL; ESTERIFICATION; FATTY ACIDS; GLYCOGEN; HEART; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; MALE; MYOCARDIUM; ORGAN SIZE; OXIDATION-REDUCTION; PERFUSION; PHOSPHOLIPIDS; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 57049159832     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90260.2008     Document Type: Article

References (69)

1. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 291: H1489-H1506, 2006.
2. Augustus AS, Kako Y, Yagyu H, Goldberg IJ. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 284: E331-E339, 2003.
3. Bar-On H, Roheim PS, Eder HA. Serum lipoproteins and apolipoproteins in rats with streptozotocin-induced diabetes. J Clin Invest 57: 714-721, 1976.
4. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 279: E1104-E1113, 2000.
5. Belke DD, Larsen TS, Lopaschuk GD, Severson DL. Glucose and fatty acid metabolism in the isolated working mouse heart. Am J Physiol Regul Integr Comp Physiol 277: R1210-R1217, 1999.
6. Bell DS. Heart failure: a serious and common comorbidity of diabetes. Clin Diabetes 22: 61-65, 2004.
7. Bennett MJ, Hauton D, Hole DG, Evans RD. Preparation of radiolabelled very-low-density lipoprotein in high yield by extended rat liver perfusion. Biotechnol Lett 22: 301-306, 2000.
8. Bennett MJ, Hauton D, Hole DG, Evans RD. Utilization of very low density lipoprotein by rat heart: the effect of endotoxin. Am J Physiol Endocrinol Metab 278: E802-E810, 2000.
9. Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 26: 2791-2795, 2003.
10. Bezman-Tarcher A, Otway S, Robinson DS. The removal of triglyceride fatty acids from incubation of the supradiaphragmatic portion of the rat. Proc R Soc Lond B Biol Sci 162: 411-426, 1965.
11. Boren J, Veniant MM, Young SG. Apo B100-containing lipoproteins are secreted by the heart. J Clin Invest 101: 1197-1202, 1998.
12. Braun JE, Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J 287: 337-347, 1992.
13. Camps L, Reina M, Llobera M, Vilaro S, Olivecrona T. Lipoprotein lipase: cellular origin and functional distribution. Am J Physiol Cell Physiol 258: C673-C681, 1990.
14. Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734: 112-126, 2005.
15. Chatham JC, Gao ZP, Forder JR. Impact of 1 wk of diabetes on the regulation of myocardial carbohydrate and fatty acid oxidation. Am J Physiol Endocrinol Metab 277: E342-E351, 1999.
16. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42: 328-335, 2003.
17. Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, Reeve JR Jr, Young NL. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 29: 1461-1473, 1988.
18. Evans RD, Ilic V, Williamson DH. Metabolic effects of platelet-activating factor in rats in vivo. Stimulation of hepatic glycogenolysis and lipogenesis. Biochem J 269: 269-272, 1990.
19. Evans RD, Wang X. Measurement of fatty acid oxidation in isolated perfused rat heart. A simple and accurate method. Biotechnol Tech 11: 127-132, 1997.
20. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25: 543-567, 2004.
21. Ghosh S, An D, Pulinilkunnil T, Qi D, Lau HC, Abrahani A, Innis SM, Rodrigues B. Role of dietary fatty acids and acute hyperglycemia in modulating cardiac cell death. Nutrition 20: 916-923, 2004.
22. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37: 693-707, 1996.
23. Hauton D, Bennett MJ, Evans RD. Utilisation of triacylglycerol and non-esterified fatty acid by the working rat heart: myocardial lipid substrate preference. Biochim Biophys Acta 1533: 99-109, 2001.
24. Howard BV. Lipoprotein metabolism in diabetes. Curr Opin Lipidol 5: 216-220, 1994.
25. Irwin D, O'Looney PA, Quinet E, Vahouny GV. Application of SDS gradient polyacrylamide slab gel electrophoresis to analysis of apolipoprotein mass and radioactivity of rat lipoproteins. Atherosclerosis 53: 163-172, 1984.
26. Junod A, Lambert AE, Stauffacher W, Renold AE. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 48: 2129-2139, 1969.
27. Kalogeris TJ, Story JA. Lymph chylomicron composition and size are modified by level of intestinally infused cholesterol and triglyceride source in rats. J Nutr 122: 1045-1055, 1992.
28. Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K, Chan L. The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49: 22-31, 2000.
29. Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, Horikoshi H, Furukawa H. Angptl3 regulates lipid metabolism in mice. Nat Genet 30: 151-157, 2002.
30. Lewin TM, Coleman RA. Regulation of myocardial triacylglycerol synthesis and metabolism. Biochim Biophys Acta 1634: 63-75, 2003.
31. Lopaschuk GD. Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate/lipid metabolism. Coron Artery Dis 7: 116-123, 1996.
32. Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7: 149-159, 2002.
33. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213: 263-276, 1994.
34. Mardy K, Belke DD, Severson DL. Chylomicron metabolism by the isolated perfused mouse heart. Am J Physiol Endocrinol Metab 281: E357-E364, 2001.
35. McEneny J, O'Kane MJ, Moles KW, McMaster C, McMaster D, Mercer C, Trimble ER, Young IS. Very low density lipoprotein subfractions in Type II diabetes mellitus: alterations in composition and susceptibility to oxidation. Diabetologia 43: 485-493, 2000.
36. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43: 1997-2006, 2002.
37. Neitzel AS, Carley AN, Severson DL. Chylomicron and palmitate metabolism by perfused hearts from diabetic mice. Am J Physiol Endocrinol Metab 284: E357-E365, 2003.
38. Nielsen LB. Lipoprotein production by the heart: a novel pathway of triglyceride export from cardiomyocytes. Scand J Clin Lab Invest Suppl 237: 35-40, 2002.
39. Nielsen LB, Bartels ED, Bollano E. Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice. J Biol Chem 277: 27014-27020, 2002.
40. Nielsen LB, Perko M, Arendrup H, Andersen CB. Microsomal triglyceride transfer protein gene expression and triglyceride accumulation in hypoxic human hearts. Arterioscler Thromb Vasc Biol 22: 1489-1494, 2002.
41. Nielsen LB, Veniant M, Boren J, Raabe M, Wong JS, Tam C, Flynn L, Vanni-Reyes T, Gunn MD, Goldberg IJ, Hamilton RL, Young SG. Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation 98: 13-16, 1998.
42. Nilsson EP, Ekman R. Rapid, simple and specific assays for lipoprotein lipase and hepatic lipase. Artery 3: 194-209, 1977.
43. Niu YG, Hauton D, Evans RD. Utilization of triacylglycerol-rich lipoproteins by the working rat heart: routes of uptake and metabolic fates. J Physiol 558: 225-237, 2004.
44. O'Looney P, Irwin D, Briscoe P, Vahouny GV. Lipoprotein composition as a component in the lipoprotein clearance defect in experimental diabetes. J Biol Chem 260: 428-432, 1985.
45. O'Looney P, Vander Maten M, Vahouny GV. Insulin-mediated modifications of myocardial lipoprotein lipase and lipoprotein metabolism. J Biol Chem 258: 12994-13001, 1983.
46. Pillarisetti S, Paka L, Sasaki A, Vanni-Reyes T, Yin B, Parthasarathy N, Wagner WD, Goldberg IJ. Endothelial cell heparanase modulation of lipoprotein lipase activity. Evidence that heparan sulfate oligosaccharide is an extracellular chaperone. J Biol Chem 272: 15753-15759, 1997.
47. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27: 169-179, 1995.
48. Rodrigues B, Severson DL. Acute diabetes does not reduce heparin-releasable lipoprotein lipase activity in perfused hearts from Wistar-Kyoto rats. Can J Physiol Pharmacol 71: 657-661, 1993.
49. Saddik M, Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 266: 8162-8170, 1991.
50. Sakamoto J, Barr RL, Kavanagh KM, Lopaschuk GD. Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart. Am J Physiol Heart Circ Physiol 278: H1196-H1204, 2000.
51. Sambandam N, Abrahani MA, Craig S, Al-Atar O, Jeon E, Rodrigues B. Metabolism of VLDL is increased in streptozotocin-induced diabetic rat hearts. Am J Physiol Heart Circ Physiol 278: H1874-H1882, 2000.
52. Sambandam N, Abrahani MA, St Pierre E, Al-Atar O, Cam MC, Rodrigues B. Localization of lipoprotein lipase in the diabetic heart: regulation by acute changes in insulin. Arterioscler Thromb Vasc Biol 19: 1526-1534, 1999.
53. Scanu AM, Edelstein C. Solubility in aqueous solutions of ethanol of the small molecular weight peptides of the serum very low density and high density lipoproteins: relevance to the recovery problem during delipidation of serum lipoproteins. Anal Biochem 44: 576-588, 1971.
54. Severson DL. Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes. Can J Physiol Pharmacol 82: 813-823, 2004.
55. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34: 25-33, 1997.
56. Taegtmeyer H, Hems R, Krebs HA. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 186: 701-711, 1980.
57. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 105: 1727-1733, 2002.
58. Takahashi S, Suzuki J, Kohno M, Oida K, Tamai T, Miyabo S, Yamamoto T, Nakai T. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 270: 15747-15754, 1995.
59. Tavangar K, Murata Y, Pedersen ME, Goers JF, Hoffman AR, Kraemer FB. Regulation of lipoprotein lipase in the diabetic rat. J Clin Invest 90: 1672-1678, 1992.
60. Teusink B, Voshol PJ, Dahlmans VE, Rensen PC, Pijl H, Romijn JA, Havekes LM. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 52: 614-620, 2003.
61. Tiebel O, Oka K, Robinson K, Sullivan M, Martinez J, Nakamuta M, Ishimura-Oka K, Chan L. Mouse very low-density lipoprotein receptor (VLDLR): gene structure, tissue-specific expression and dietary and developmental regulation. Atherosclerosis 145: 239-251, 1999.
62. Tomkin GH, Owens D. Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 17: 27-43, 2001.
63. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 44: 103-150, 1992.
64. Unger RH. Lipotoxic diseases. Annu Rev Med 53: 319-336, 2002.
65. van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 45: 279-293, 2000.
66. Xiang SQ, Cianflone K, Kalant D, Sniderman AD. Differential binding of triglyceride-rich lipoproteins to lipoprotein lipase. J Lipid Res 40: 1655-1663, 1999.
67. Yokoyama M, Yagyu H, Hu Y, Seo T, Hirata K, Homma S, Goldberg IJ. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem 279: 4204-4211, 2004.
68. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 105: 1861-1870, 2002.
69. Zechner R. The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. Curr Opin Lipidol 8: 77-88, 1997.